Safety and immunogenicity of Salmonella typhimurium expressing C-terminal truncated human IL-2 in a murine model

Biologics: Targets and Therapy

Volumn 4, Issue , 2010, Pages 61-73

  Sorenson, Brent ^a   Banton, Kaysie ^a   Augustin, Lance ^a   Barnett, Sean ^a   McCulloch, Karen ^a   Dorn, Joshua ^a   Frykman, Natalie ^a   Leonard, Arnold ^a   Saltzman, Daniel ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Interleukin 2; Natural killer cells; Salmonella typhimurium

Indexed keywords

INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD CELL COUNT; CANCER GENE THERAPY; CARBOXY TERMINAL SEQUENCE; CELL FUNCTION; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG SAFETY; FEMALE; HISTOPATHOLOGY; IMMUNOGENICITY; LIVER METASTASIS; LUNG METASTASIS; LYMPHOCYTE PROLIFERATION; METASTASIS INHIBITION; MOUSE; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OSTEOSARCOMA; PROTEIN EXPRESSION; SALMONELLA TYPHIMURIUM; SINGLE DRUG DOSE; T LYMPHOCYTE SUBPOPULATION;

EID: 77951148564     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/btt.s9121     Document Type: Article

References (37)

1. Horner MJ, Ries LAG, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2006, based on November 2008 SEER data submission, posted to the SEER Website, 2009. Bethesda, MD: National Cancer Institute; 2009. Available from: http://seer.cancer.gov/csr/1975_2006/. Accessed on December 10, 2009
2. Ferguson WS, Harris MB, Goorin AM, et al. Presurgical window of carboplatin and surgery and multidrug chemotherapy for the treatment of newly diagnosed metastatic or unresectable osteosarcoma: Pediatric Oncology Group Trial. J Pediatr Hematol Oncol. 2001;23(6):340-348.
3. Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev. 2006;32(6):423-436.
4. Bermudes D, Low B, Pawelek J. Tumor-targeted Salmonella. Highly selective delivery vectors. Adv Exp Med Biol. 2000;465:57-63.
5. Soto LJ 3rd, Sorenson BS, Nelson BW, Solis SJ, Leonard AS, Saltzman DA. Preferential proliferation of attenuated Salmonella typhimurium within neuroblastoma. J Pediatr Surg. 2004;39(6): 937-940; discussion 937-940.
6. Kasinskas RW, Forbes NS. Salmonella typhimurium specifically chemotax and proliferate in heterogeneous tumor tissue in vitro. Biotechnol Bioeng. 2006;94(4):710-721.
7. Sorenson BS, Banton KL, Frykman NL, Leonard AS, Saltzman DA. Attenuated Salmonella typhimurium with IL-2 gene reduces pulmonary metastases in murine osteosarcoma. Clin Orthop Relat Res. 2008;466(6):1285-1291.
8. Sorenson BS, Banton KL, Frykman NL, Leonard AS, Saltzman DA. Attenuated Salmonella typhimurium with interleukin 2 gene prevents the establishment of pulmonary metastases in a model of osteosarcoma. J Pediatr Surg. 2008;43(6):1153-1158.
9. Soto LJ 3rd, Sorenson BS, Kim AS, Feltis BA, Leonard AS, Saltzman DA. Attenuated Salmonella typhimurium prevents the establishment of unresectable hepatic metastases and improves survival in a murine model. J Pediatr Surg. 2003;38(7):1075-1079.
10. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol. 2000;164(12): 6166-6173.
11. Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, Papaioannou VE. RAG-1-deficient mice have no mature B and T lymphocytes. Cell. 1992;68(5):869-877.
12. Ren Z, Gay R, Thomas A, et al. Effect of age on susceptibility to Salmonella Typhimurium infection in C57BL/6 mice. J Med Microbiol. 2009;58(Pt 12):1559-1567.
13. Khanna C, Prehn J, Yeung C, Caylor J, Tsokos M, Helman L. An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential. Clin Exp Metastasis. 2000;18(3):261-271.
14. Rescigno M, Urbano M, Valzasina B, et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol. 2001;2(4):361-367.
15. Vazquez-Torres A, Jones-Carson J, Baumler AJ, et al. Extraintestinal dissemination of Salmonella by CD18-expressing phagocytes. Nature. 1999;401(6755):804-808.
16. Tsolis RM, Kingsley RA, Townsend SM, Ficht TA, Adams LG, Baumler AJ. Of mice, calves, and men. Comparison of the mouse typhoid model with other Salmonella infections. Adv Exp Med Biol. 1999;473:261-274.
17. Sheppard M, Webb C, Heath F, et al. Dynamics of bacterial growth and distribution within the liver during Salmonella infection. Cell Microbiol. 2003;5(9):593-600.
18. Grant AJ, Sheppard M, Deardon R, et al. Caspase-3-dependent phagocyte death during systemic Salmonella enterica serovar Typhimurium infection of mice. Immunology. 2008;125(1):28-37
19. Dunlap NE, Benjamin WH Jr, McCall RD Jr, Tilden AB, Briles DE. A 'safe-site' for Salmonella typhimurium is within splenic cells during the early phase of infection in mice. Microb Pathog. 1991;10(4):297-310.
20. Chou CK, Hung JY, Liu JC, Chen CT, Hung MC. An attenuated Salmonella oral DNA vaccine prevents the growth of hepatocellular carcinoma and colon cancer that express alpha-fetoprotein. Cancer Gene Ther. 2006;13(8):746-752.
21. Hormaeche CE. Live attenuated Salmonella vaccines and their potential as oral combined vaccines carrying heterologous antigens. J Immunol Methods. 1991; 142(1):113-120.
22. Huang Y, Hajishengallis G, Michalek SM. Induction of protective immunity against Streptococcus mutans colonization after mucosal immunization with attenuated Salmonella enterica serovar typhimurium expressing an S. mutans adhesin under the control of in vivo-inducible nirB promoter. Infect Immun. 2001;69(4):2154-2161.
23. Xu C, Li ZS, Du YQ, et al. Construction of recombinant attenuated Salmonella typhimurium DNA vaccine expressing H pylori ureB and IL-2. World J Gastroenterol. 2007;13(6):939-944.
24. Saltzman DA, Heise CP, Hasz DE, et al. Attenuated Salmonella typhimurium containing interleukin-2 decreases MC-38 hepatic metastases: a novel anti-tumor agent. Cancer Biother Radiopharm. 1996;11(2):145-153.
25. Saltzman DA, Katsanis E, Heise CP, et al. Patterns of hepatic and splenic colonization by an attenuated strain of Salmonella typhimurium containing the gene for human interleukin-2: a novel anti-tumor agent. Cancer Biother Radiopharm. 1997;12(1):37-45.
26. Saltzman DA, Katsanis E, Heise CP, et al. Antitumor mechanisms of attenuated Salmonella typhimurium containing the gene for human interleukin-2: a novel antitumor agent? J Pediatr Surg. 1997;32 (2):301-306.
27. Nishikawa H, Sato E, Briones G, et al. In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines. J Clin Invest. 2006;116(7):1946-1954.
28. Loeffler M, Le'Negrate G, Krajewska M, Reed JC. Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth. Proc Natl Acad Sci USA. 2007;104(31):12879-12883.
29. Saltzman DA. Cancer immunotherapy based on the killing of Salmonella typhimurium-infected tumour cells. Expert Opin Biol Ther. 2005;5(4):443-449.
30. Curtiss R 3rd, Kelly SM. Salmonella typhimurium deletion mutants lacking adenylate cyclase and cyclic AMP receptor protein are avirulent and immunogenic. Infect Immun. 1987;55(12):3035-3043
31. Belyakov IM, Ahlers JD. What role does the route of immunization play in the generation of protective immunity against mucosal pathogens? J Immunol. 2009;183(11):6883-6892.
32. Martinoli C, Chiavelli A, Rescigno M. Entry route of Salmonella typhimurium directs the type of induced immune response. Immunity. 2007;27(6):975-984.
33. Feltis BA, Miller JS, Sahar DA, et al. Liver and circulating NK1.1(+)CD3(-) cells are increased in infection with attenuated Salmonella typhimurium and are associated with reduced tumor in murine liver cancer. J Surg Res. 2002;107(1):101-107.
34. Pawelek JM, Low KB, Bermudes D. Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res. 1997;57(20):4537-4544.
35. Gentschev I, Fensterle J, Schmidt A, et al. Use of a recombinant Salmonella enterica serovar Typhimurium strain expressing C-Raf for protection against C-Raf induced lung adenoma in mice. BMC Cancer. 2005;5:15.
36. Clairmont C, Lee KC, Pike J, et al. Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium. J Infect Dis. 2000;181(6):1996-2002.
37. Toso JF, Gill VJ, Hwu P, et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol. 2002;20(1):142-152.